{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:13:15Z","timestamp":1753877595146,"version":"3.41.2"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Continuing antifungal prophylaxis (AFPx) to prevent invasive mold infections (IMIs) in recipients of allogeneic hematopoietic cell transplantation (alloHCT) after primary hospital discharge from alloHCT admission varies among transplant centers despite recommendations to continue prophylaxis through day +75. Characteristics driving AFPx prescribing at hospital discharge and outcomes are unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this retrospective analysis, we reviewed patients continuing AFPx vs no AFPx at hospital discharge. We included patients with a hospital stay \u22657 days and \u226440 days. We excluded patients with a history of IMI prior to alloHCT, new IMI during admission, or death prior to discharge. Our primary objective was incidence of probable or proven IMI per the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Our secondary objectives were nonrelapse mortality at day +100, overall survival at day +100, and characteristics driving AFPx discontinuation at hospital discharge.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 430 patients identified, 387 met inclusion criteria. At discharge, 56% (217\/387) continued AFPx, and 44% (170\/387) had no AFPx. At day +100, 3 probable IMI cases occurred in the group with continued AFPx vs 1 probable IMI case in the no-AFPx group (no proven IMI). Univariate analysis showed no difference in cumulative incidence of probable IMI (P = .440), nonrelapse mortality (P = .072), and overall survival (P = .855) between groups. Multivariable logistic regression demonstrated that patients were less likely to continue AFPx if they had a diagnosis other than acute myeloid leukemia, a length of stay \u226430 days, acute graft-vs-host disease grade 0 or 1, and corticosteroid use \u22645 days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There was no difference in probable IMI at day +100 after alloHCT based on continuing vs discontinuing AFPx at hospital discharge after alloHCT admission supporting a risk-adapted prophylaxis approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae409","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T08:33:11Z","timestamp":1721723591000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-6380","authenticated-orcid":false,"given":"Justine Abella","family":"Ross","sequence":"first","affiliation":[{"name":"Department of Pharmacy, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyan","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3704-1733","authenticated-orcid":false,"given":"Bernard","family":"Tegtmeier","sequence":"additional","affiliation":[{"name":"Department of Quality Risk and Regulatory Management, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4310-3275","authenticated-orcid":false,"given":"Deepa","family":"Nanayakkara","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-1573","authenticated-orcid":false,"given":"Jana","family":"Dickter","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8887-6482","authenticated-orcid":false,"given":"Ricardo","family":"Spielberger","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-3424","authenticated-orcid":false,"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-4152","authenticated-orcid":false,"given":"Stephen J","family":"Forman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0109-5991","authenticated-orcid":false,"given":"Randy","family":"Taplitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr","family":"Al Malki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-0568","authenticated-orcid":false,"given":"Sanjeet Singh","family":"Dadwal","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2024082915084400500_ofae409-B1","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"2024082915084400500_ofae409-B2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024082915084400500_ofae409-B3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2024082915084400500_ofae409-B4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1086\/591969","article-title":"Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation","volume":"47","author":"Garcia-Vidal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024082915084400500_ofae409-B5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","article-title":"American society of transplantation and cellular therapy series, 2: management and prevention of aspergillosis in hematopoietic cell transplantation recipients","volume":"27","author":"Dadwal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2024082915084400500_ofae409-B6","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2024082915084400500_ofae409-B7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37201\/req\/013.2023","article-title":"Recommendations on the use of azole antifungals in hematology-oncology patients","volume":"36","author":"Azanza","year":"2023","journal-title":"Rev Esp Quimioter"},{"key":"2024082915084400500_ofae409-B8","doi-asserted-by":"crossref","first-page":"e13148","DOI":"10.1111\/tid.13148","article-title":"Cost-effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant","volume":"21","author":"Walker","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2024082915084400500_ofae409-B9","doi-asserted-by":"crossref","first-page":"ofab596","DOI":"10.1093\/ofid\/ofab596","article-title":"Invasive mold infections in allogeneic hematopoietic cell transplant recipients in 2020: have we made enough progress?","volume":"9","author":"Roth","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024082915084400500_ofae409-B10","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1080\/14787210.2016.1245613","article-title":"Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field","volume":"14","author":"Douglas","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024082915084400500_ofae409-B11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024082915084400500_ofae409-B12","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"key":"2024082915084400500_ofae409-B13","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.bbmt.2017.06.012","article-title":"Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of \u201cRISK\u201d study","volume":"23","author":"Choi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024082915084400500_ofae409-B14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/8755122519859976","article-title":"Adherence to antifungal guidelines in malignant hematology patients: a review of the literature","volume":"35","author":"Reslan","year":"2019","journal-title":"J Pharm Technol"},{"key":"2024082915084400500_ofae409-B15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024082915084400500_ofae409-B16","doi-asserted-by":"crossref","first-page":"e12981","DOI":"10.1111\/tid.12981","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: a Swiss transplant cohort study","volume":"20","author":"Kuster","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2024082915084400500_ofae409-B17","doi-asserted-by":"crossref","first-page":"ofad424","DOI":"10.1093\/ofid\/ofad424","article-title":"Real-world use of mold-active triazole prophylaxis in the prevention of invasive fungal diseases: results from a subgroup analysis of a multicenter national registry","volume":"10","author":"Nguyen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024082915084400500_ofae409-B18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2024082915084400500_ofae409-B19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"2024082915084400500_ofae409-B20","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the transplant-associated infection surveillance network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024082915084400500_ofae409-B21","doi-asserted-by":"crossref","first-page":"ofab502","DOI":"10.1093\/ofid\/ofab502","article-title":"SUBA-Itraconazole for primary antifungal prophylaxis after allogeneic hematopoietic cell transplantation","volume":"8","author":"Lindsay","year":"2021","journal-title":"Open Forum Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae409\/58612680\/ofae409.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/8\/ofae409\/58875026\/ofae409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/8\/ofae409\/58875026\/ofae409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T20:58:23Z","timestamp":1724965103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae409\/7717710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae409","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,23]]},"article-number":"ofae409"}}